The Pfizer-BioNTech vaccine was 100% effective in preventing COVID-19 among children ages 12 to 15 in a phase 3 trial, the companies announced on Wednesday (March 31). The companies plan to submit the data to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) “as soon as possible” to expand emergency